Bulk Manufacturer of Controlled Substances Application: Continuus Pharmaceutical, 48511 [2022-16989]

Download as PDF 48511 Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Massachusetts 01801, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Kristi O’Malley, Assistant Administrator. The company plans to bulk manufacture the above listed controlled substance for research and development purposes only. No other activities for these drug codes are authorized for this registration. [FR Doc. 2022–16984 Filed 8–8–22; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE 9801 II BILLING CODE P Bulk Manufacturer of Controlled Substances Application: Continuus Pharmaceutical DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: [Docket No. DEA–1056] Continuus Pharmaceutical has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 11, 2022. Such persons may also file a written request for a hearing on the application on or before October 11, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 8, 2022, Continuus Pharmaceutical, 25–R Olympia Avenue, Woburn, SUMMARY: jspears on DSK121TN23PROD with NOTICES Schedule [FR Doc. 2022–16989 Filed 8–8–22; 8:45 am] [Docket No. DEA–1037] 18:04 Aug 08, 2022 Fentanyl ........................... Drug code Kristi O’Malley, Assistant Administrator. Drug Enforcement Administration VerDate Sep<11>2014 Controlled substance Jkt 256001 Bulk Manufacturer of Controlled Substances Application: Biopharmaceutical Research Company Drug Enforcement Administration, Justice. ACTION: Notice of application. successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June 8, 2022, Biopharmaceutical Research Company, 11045 Commercial Parkway, Castroville, California 95012–3209, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance Marihuana Extract .............. Marihuana .......................... Tetrahydrocannabinols ...... Drug code 7350 7360 7370 Schedule I I I The company plans to bulk manufacture the listed controlled substances to provide Pharmaceuticalgrade marihuana in order to facilitate research in a manner that complies with local, state and federal regulations. No other activities for these drug codes are authorized for this registration. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–16995 Filed 8–8–22; 8:45 am] BILLING CODE P AGENCY: DEPARTMENT OF JUSTICE Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 11, 2022. Such persons may also file a written request for a hearing on the application on or before October 11, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been SUMMARY: PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Drug Enforcement Administration [Docket No. DEA–1059] Importer of Controlled Substances Application: Curium US LLC Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Curium US LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. SUMMARY: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 8, 2022. Such persons may also file a written request for a hearing on the application on or before September 8, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow DATES: E:\FR\FM\09AUN1.SGM 09AUN1

Agencies

[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Page 48511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16989]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1037]


Bulk Manufacturer of Controlled Substances Application: Continuus 
Pharmaceutical

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Continuus Pharmaceutical has applied to be registered as a 
bulk manufacturer of basic class(es) of controlled substance(s). Refer 
to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
October 11, 2022. Such persons may also file a written request for a 
hearing on the application on or before October 11, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on April 8, 2022, Continuus Pharmaceutical, 25-R Olympia 
Avenue, Woburn, Massachusetts 01801, applied to be registered as a bulk 
manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Fentanyl................................    9801  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above listed controlled 
substance for research and development purposes only. No other 
activities for these drug codes are authorized for this registration.

Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-16989 Filed 8-8-22; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.